CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes

Claire Lacan; Jonathan Caron; Nadine Tarantino; Baptiste Fouquet; Mustapha Cherai; Christophe Parizot; Véronique Morel; Laetitia Souchet; Madalina Uzunov; Guy Gorochov; Stéphanie Nguyen-Quoc; Elise Sourdeau; Vincent Vieillard; Makoto Miyara; Angélique Vinit; Silvia Solorzano; Carole Soussain; Caroline Houillier; Carole Metz; Brigitte Autran; Elena Litvinova; Magali Le Garff-Tavernier; Françoise Norol; Damien Roos-Weil; Sylvan Choquet; Amélie Guihot; Marine Baron

doi:10.3324/haematol.2023.282875

CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes

Haematologica. 2023 Dec 1;108(12):3485-3490. doi: 10.3324/haematol.2023.282875.

Authors

Claire Lacan¹, Jonathan Caron², Nadine Tarantino³, Baptiste Fouquet⁴, Mustapha Cherai⁴, Christophe Parizot⁴, Véronique Morel⁵, Laetitia Souchet⁵, Madalina Uzunov⁵, Guy Gorochov⁴, Stéphanie Nguyen-Quoc⁶, Elise Sourdeau⁷, Vincent Vieillard³, Makoto Miyara⁴, Angélique Vinit⁸, Silvia Solorzano⁵, Carole Soussain⁹, Caroline Houillier¹⁰, Carole Metz¹¹, Brigitte Autran³, Elena Litvinova⁴, Magali Le Garff-Tavernier¹², Françoise Norol⁵, Damien Roos-Weil⁵, Sylvan Choquet⁵, Amélie Guihot³, Marine Baron¹³

Affiliations

¹ Sorbonne Université, Inserm U1135, CNRS EMR 8255, CIMI-Paris, F-75013 Paris, France; Sorbonne Université, Department of Clinical Haematology, AP-HP, Pitié- Salpêtrière Hospital, F-75013 Paris France.
² Centre de recherche des Cordeliers, INSERM, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Sorbonne Université, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Paris.
³ Sorbonne Université, Inserm U1135, CNRS EMR 8255, CIMI-Paris, F-75013 Paris.
⁴ Sorbonne Université, Department of Immunology, AP-HP, Pitié- Salpêtrière Hospital, F-75013 Paris.
⁵ Sorbonne Université, Department of Clinical Haematology, AP-HP, Pitié- Salpêtrière Hospital, F-75013 Paris France.
⁶ Sorbonne Université, Inserm U1135, CNRS EMR 8255, CIMI-Paris, F-75013 Paris, France.; Sorbonne Université, Department of Clinical Haematology, AP-HP, Pitié- Salpêtrière Hospital, F-75013 Paris France.
⁷ Sorbonne Université, Department of Biological Haematology, AP-HP, Pitié- Salpêtrière Hospital, F-75013 Paris.
⁸ Sorbonne Université, UMS37-PASS, Plateforme de cytométrie CyPS, Pitié-Salpêtrière Hospital, F-75013 Paris.
⁹ Hematology Unit, Institut Curie, site de Saint-Cloud et Center for Cancer Immunotherapy, Institut Curie, PSL Research University, INSERM U932, Paris.
¹⁰ Sorbonne Université, INSERM, CNRS, UMR S 1127, Institut du Cerveau, ICM, Department of Neurology 2-Mazarin, AP-HP, Pitié Salpêtrière Hospital, F-75013 Paris.
¹¹ Sorbonne Université, Unité REQPHARM, Pharmacie à Usage Intérieur, AP-HP, Pitié-Salpêtrière Hospital, F-75013 Paris France.
¹² Centre de recherche des Cordeliers, INSERM, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Sorbonne Université, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Paris, France; Sorbonne Université, Department of Biological Haematology, AP-HP, Pitié- Salpêtrière Hospital, F-75013 Paris.
¹³ Sorbonne Université, Inserm U1135, CNRS EMR 8255, CIMI-Paris, F-75013 Paris, France.; Sorbonne Université, Department of Clinical Haematology, AP-HP, Pitié- Salpêtrière Hospital, F-75013 Paris France. marine.baron@aphp.fr.

No abstract available

MeSH terms

Biology
Central Nervous System
Central Nervous System Neoplasms* / therapy
Cerebrospinal Fluid
Humans
Immunotherapy, Adoptive / adverse effects
Lymphoma, Non-Hodgkin*

Grants and funding

Funding: This study was supported by grants from INCA-DGOS-Inserm_12560 (SiRIC CURAMUS is financially supported by the French National Cancer Institute, the French Ministry of Solidarity and Health and INSERM with financial support from ITMO Cancer AVIESAN), by Association Capucine and SFGM-TC, prix Force Hémato 2020 and by the Fondation ARC pour la recherche sur le cancer (to DRW). JC was financially supported by SiRIC CURAMUS.